Хуудас 1 -аас 294 үр дүн
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a U.S. National Phase application under 35 U.S.C. .sctn.371 of PCT Application No. PCT/GB02/04201, filed Sep. 13, 2002, which claims priority under 35 U.S.C. .sctn.119 from GB Application No. 0122696.8, filed Sep. 20, 2001.
The present
FIELD OF THE INVENTION
The present disclosure relates generally to field of neurobiology. Specifically, the present disclosure relates to novel compositions and methods of modulating TrkB signaling and inhibiting TrkB-mediated activation of phospholipase C.gamma.1 (PLC.gamma.1) for the treatment of
INTRODUCTION
I. Field of the Invention
The present invention relates to: cells and non-human animals deficient for the protein kinase C isozyme .epsilon. (PKC.epsilon.); the use of PKC.epsilon. as a target for drugs; the use of modulators of PKC.epsilon. in methods of reducing anxiety, modulating
INTRODUCTION
FIELD OF THE INVENTION
The present invention relates to: cells and non-human animals deficient for the protein kinase C isozyme .epsilon. (PKC.epsilon.); the use of PKC.epsilon. as a target for drugs; the use of modulators of PKC.epsilon. in methods of reducing anxiety, modulating
FIELD OF THE INVENTION
Aspects of the present invention relate generally to alcohol withdrawal syndrome (AWS), and isoprenoid-based compounds, and more particularly to pharmaceutical compositions comprising calcium channel blockers (e.g., isoprenoids such as farnesol and/or farnesol analogues or
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention is to imidazo[1,5-a]quinolines which are useful pharmaceutical agents for the treatment of anxiety, sleep disorders, panic states, convulsions and muscle disorders.
2. Description of the Related Art
EP 283,162 discloses
FIELD OF THE INVENTION
The invention provides cyclohexylamine derivatives as N-Methyl-D-Aspartate (NMDA) antagonists, pharmacological compositions comprising the derivatives, and methods of treating diseases and disorders responsive to antagonism of NMDA receptors using the derivatives.
BACKGROUND
Voltage gated calcium channels (VGCC) mediate Ca.sup.2+ entry into cells in response to membrane depolarization (Catterall, W. A.(1988) Science 242:50-61 and Bean B P. (1989) Annu. Rev. Physiol. 51:367-368). Ca.sup.2+ entering the cell through voltage-gated Ca.sup.2+ channels serves as the second
This application claims benefit of U.S. provisional application Ser. No. 60/013,813 filed Mar. 21, 1996.
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention is in the field of medicinal chemistry. In particular, the invention relates to novel substituted 2,3-benzodiazepin-4-ones.
FIELD OF THE INVENTION
The present invention relates to the administration of benzodiazepines such as midazolam. In particular, the invention provides improved midazolam compositions for intranasal administration comprising high concentrations of midazolam.
DISCUSSION OF THE PRIOR ART
Midazolam is a
FIELD OF THE INVENTION
The invention relates to new therapeutic techniques involving eslicarbazepine acetate or eslicarbazepine.
BACKGROUND OF THE INVENTION
An epileptic seizure is defined as a clinical event associated with a transient, hypersynchronous neuronal discharge. The seizure represents
This invention relates to 4,5-dihydro-4-heteroaryl-3H-1,3-benzodiazepines. More particularly, this invention relates to 4,5-dihydro-4-heteroaryl-3H-1,3-benzodiazepines of the formula: ##STR1## wherein Ar is a radical selected from the group consisting of ##STR2## wherein R.sup.2 is hydrogen,
This invention relates to 4,5-dihydro-4-heteroaryl-3H-1,3-benzodiazepines. More particularly, this invention relates to 4,5-dihydro-4-heteroaryl-3H-1,3-benzodiazepines of the formula: ##STR1## wherein Ar is a radical selected from the group consisting of ##STR2## wherein R.sup.2 is hydrogen,
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention relates to a composition for preventing or treating a psychiatric disorder comprising a phenyl carbamate compound and a method for preventing or treating a psychiatric disorder therewith.
Description of the Related
This is an application under 35 U.S.C. 371 of PCT/GB99/01827 and claims priority from Great Britain Application No. 9813006.5, filed Jun. 16, 1998.
BACKGROUND
The present invention relates to a class of substituted triazolo-pyrimidine derivatives and to their use in therapy. More particularly, this